Little is known about the factors associated with patient compliance with nucleos(t)ide analog (NUC) treatment for chronic hepatitis B (CHB). The purpose of this study was to examine the association between sociodemographic and clinical characteristics and adherence to NUCs among patients with CHB. A total of 211 CHB patients receiving NUC monotherapy were asked to report the number of prescrib...

Abstract Background Entecavir (ETV) is recommended as a first-line anti-HBV treatment. However, many chronic hepatitis B patients initiate treatment such lamivudine and telbivudine with low genetic barriers in China, which leads to compensatory mutations increases the rate of ETV resistance. The management resistance China an essential clinical issue. Methods Patients from 2011 2017 nucleos(t)i...

Hepatitis B virus (HBV) infection is common in HIV-infected persons and is associated with increased risk of liver-related morbidity and mortality. Agents available to treat HBV infection in coinfected patients include lamivudine, entecavir, emtricitabine, adefovir, peginterferon alfa, and the recently approved telbivudine. Treatment decisions should take into account a number of factors, inclu...

Several next-generation nucleoside and nucleotide analogues are currently in clinical development for the treatment of chronic hepatitis B. However, the efficacy of newer agents against lamivudine-resistant hepatitis B virus (HBV) has not been fully explored. To investigate this in vitro, we generated novel stable cell lines expressing HBV encoding the four major patterns of lamivudine resistan...

Title: Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission Authors: Weihui Sun ([email protected]) Zhao Shangfei ([email protected]) Ma Lei ([email protected]) Hao Anhua ([email protected]) Zhao Bo ([email protected]) Zhou Lin ([email protected]) Qu Qiaoyan ([email protected]) Song Mingquan ([email protected]) Xin Yongning (xinyongni...